Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
ONTY's Cash to Debt is ranked higher than
100% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. ONTY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ONTY' s Cash to Debt Range Over the Past 10 Years
Min: 5.92  Med: 170.56 Max: No Debt
Current: No Debt
Interest Coverage No Debt
ONTY's Interest Coverage is ranked higher than
100% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ONTY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ONTY' s Interest Coverage Range Over the Past 10 Years
Min: 976.29  Med: 9999.50 Max: 9999.99
Current: No Debt
976.29
9999.99
F-Score: 4
Z-Score: -4.58
M-Score: -1.62
WACC vs ROIC
17.83%
-133.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -41.53
ONTY's ROE (%) is ranked lower than
58% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. ONTY: -41.53 )
Ranked among companies with meaningful ROE (%) only.
ONTY' s ROE (%) Range Over the Past 10 Years
Min: -163.15  Med: -64.90 Max: 43.53
Current: -41.53
-163.15
43.53
ROA (%) -36.52
ONTY's ROA (%) is ranked lower than
60% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. ONTY: -36.52 )
Ranked among companies with meaningful ROA (%) only.
ONTY' s ROA (%) Range Over the Past 10 Years
Min: -80.5  Med: -50.43 Max: 23.29
Current: -36.52
-80.5
23.29
ROC (Joel Greenblatt) (%) -2045.38
ONTY's ROC (Joel Greenblatt) (%) is ranked lower than
70% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. ONTY: -2045.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ONTY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3364.41  Med: -2040.51 Max: 635.37
Current: -2045.38
-3364.41
635.37
EBITDA Growth (3Y)(%) 92.10
ONTY's EBITDA Growth (3Y)(%) is ranked higher than
97% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. ONTY: 92.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ONTY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -60  Med: -8.30 Max: 92.1
Current: 92.1
-60
92.1
EPS Growth (3Y)(%) 74.00
ONTY's EPS Growth (3Y)(%) is ranked higher than
96% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. ONTY: 74.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ONTY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -56.1  Med: -8.50 Max: 74
Current: 74
-56.1
74
» ONTY's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ONTY Guru Trades in Q2 2015

Paul Tudor Jones 63,257 sh (+175.55%)
Murray Stahl 33,333 sh (unchged)
First Eagle Investment Sold Out
Steven Cohen Sold Out
Jim Simons 474,192 sh (-22.79%)
» More
Q3 2015

ONTY Guru Trades in Q3 2015

Murray Stahl 33,333 sh (unchged)
Jim Simons 339,800 sh (-28.34%)
Paul Tudor Jones 44,060 sh (-30.35%)
» More
Q4 2015

ONTY Guru Trades in Q4 2015

First Eagle Investment 300,000 sh (New)
Paul Tudor Jones 48,760 sh (+10.67%)
Jim Simons Sold Out
Murray Stahl Sold Out
» More
Q1 2016

ONTY Guru Trades in Q1 2016

Paul Tudor Jones 48,760 sh (unchged)
First Eagle Investment 300,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ONTY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:FBIO, TPE:1734, XPAR:CEREN, XBRU:THR, XKRX:067370, XKRX:142760 » details
Traded in other countries:3O6.Germany,
Oncothyreon Inc is a clinical-stage biopharmaceutical company. It develops and commercialize synthetic vaccines & small molecules that treat the lives & outcomes of cancer patients.

Oncothyreon Inc was incorporated on September 7, 2007. The Company is a clinical-stage biopharmaceutical company that develops therapeutic products for the treatment of cancer. Its cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. The Company's cancer vaccine product candidate, tecemotide, formerly known as L-BLP25 or Stimuvax, is being evaluated for the treatment of non-small cell lung cancer, or NSCLC. It has granted license to Merck KGaA of Darmstadt, Germany, or Merck KGaA, for the development, manufacture and commercialization of tecemotide. The Company is also conducting Phase 1 trial for ONT-10, a cancer vaccine. The Company's pipeline of products includes immunotherapies and small molecules. The Company currently outsources the manufacturing of drug substances and drug products for all of its products in clinical development. As of December 31, 2013 the Company owned approximately 25 U.S. patents and patent applications. It competes with pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations which are developing various approaches to cancer therapy. In addition to regulations in the United States, the Company will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its product candidates.

Ratios

vs
industry
vs
history
P/B 1.45
ONTY's P/B is ranked higher than
84% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. ONTY: 1.45 )
Ranked among companies with meaningful P/B only.
ONTY' s P/B Range Over the Past 10 Years
Min: 0.74  Med: 4.14 Max: 23.59
Current: 1.45
0.74
23.59
Current Ratio 8.83
ONTY's Current Ratio is ranked higher than
73% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. ONTY: 8.83 )
Ranked among companies with meaningful Current Ratio only.
ONTY' s Current Ratio Range Over the Past 10 Years
Min: 1.67  Med: 11.89 Max: 36.71
Current: 8.83
1.67
36.71
Quick Ratio 8.83
ONTY's Quick Ratio is ranked higher than
74% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. ONTY: 8.83 )
Ranked among companies with meaningful Quick Ratio only.
ONTY' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 11.89 Max: 36.71
Current: 8.83
0.95
36.71

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.26
ONTY's Price/Net Cash is ranked higher than
72% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. ONTY: 3.26 )
Ranked among companies with meaningful Price/Net Cash only.
ONTY' s Price/Net Cash Range Over the Past 10 Years
Min: 1.04  Med: 5.43 Max: 38.63
Current: 3.26
1.04
38.63
Price/Net Current Asset Value 3.08
ONTY's Price/Net Current Asset Value is ranked higher than
73% of the 783 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. ONTY: 3.08 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ONTY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.91  Med: 5.18 Max: 38
Current: 3.08
0.91
38
Price/Tangible Book 2.92
ONTY's Price/Tangible Book is ranked higher than
65% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. ONTY: 2.92 )
Ranked among companies with meaningful Price/Tangible Book only.
ONTY' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.84  Med: 4.64 Max: 73.64
Current: 2.92
0.84
73.64
Earnings Yield (Greenblatt) (%) -61.17
ONTY's Earnings Yield (Greenblatt) (%) is ranked lower than
88% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. ONTY: -61.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ONTY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -66.25  Med: 35.30 Max: 6723.4
Current: -61.17
-66.25
6723.4

More Statistics

EPS (TTM) $ -0.40
Beta2.13
Short Percentage of Float10.58%
52-Week Range $0.90 - 4.69
Shares Outstanding (Mil)94.96

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $)
EPS ($) -0.41 -0.43 -0.43
EPS without NRI ($) -0.41 -0.43 -0.43
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for ONTY

Headlines

Articles On GuruFocus.com
Value Betting with Special Situations: Lessons from the World of Gambling Mar 05 2013 
Cubist Pharmaceutical - Acutely Aware May 09 2010 

More From Other Websites
ONCOTHYREON INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... May 19 2016
ONCOTHYREON INC. Financials May 17 2016
ONCOTHYREON INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 09 2016
Oncothyreon Reports First Quarter 2016 Financial Results & Provides Corporate Update May 09 2016
Oncothyreon reports 1Q loss May 09 2016
Oncothyreon reports 1Q loss May 09 2016
Oncothyreon Reports First Quarter 2016 Financial Results & Provides Corporate Update May 09 2016
4 Biotech Stocks to Buy at Beaten Down Prices Apr 26 2016
Oncothyreon (ONTY) Catches Eye: Stock Moves 11.6% Higher Apr 26 2016
Oncothyreon Highlights Novel Checkpoint Kinase 1 Inhibitors at American Association for Cancer... Apr 19 2016
Oncothyreon Highlights Novel Checkpoint Kinase 1 Inhibitors at American Association for Cancer... Apr 19 2016
5 Stocks Under $10 Set to Soar Apr 14 2016
ONCOTHYREON INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Apr 01 2016
Seattle biotech Oncothyreon names new CEO Mar 29 2016
Oncothyreon Appoints Scott D. Myers Chief Executive Officer Mar 29 2016
ONCOTHYREON INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Mar 29 2016
Oncothyreon Appoints Scott D. Myers Chief Executive Officer Mar 29 2016
Stocks To Buy: These Are Being Considered on Monday 3/21/2016 Mar 21 2016
Three Stocks To Watch Friday Afternoon 3/18/2016 Mar 18 2016
ONCOTHYREON INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)